DL-2-Hydroxybutyric Acid Sodium Salt

We are DL-2-Hydroxybutyric Acid Sodium Salt CAS:5094-24-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:DL-2-Hydroxybutyric Acid Sodium Salt
CAS.NO:5094-24-6
Synonyms:DL-2-Hydroxybutyric Acid Sodium Salt
Sodium 2-hydroxybutanoate
SODIUM 2-HYDROXYBUTYRATE
Sodium DL-2-Hydroxybutyrate
2-Hydroxybutyric acid sodium salt
 
Physical and Chemical Properties:
Density 1.195g/cm3
Boiling Point 238.3ºC at 760mmHg
Melting Point 133-135 °C(lit.)
Molecular Formula C4H7NaO3
Molecular Weight 126.086
Flash Point 112.2ºC
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Idelalisib(CAS:870281-82-6).

DL-2-Hydroxybutyric Acid Sodium Salt


Related News: Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.Beta-hidroxi-beta-metilbutirato de calcio CAS:135236-72-5 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.1-pyridin-3-ylethanone Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.4065-45-6 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.

Related Products
Product Name
[diacetyloxy(propyl)silyl] acetate View Details
furan-2-ylmethyl 2-methylprop-2-enoate View Details
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodec-1-ene Cas:21652-58-4 View Details
Cyanidin manufacturer (ethyldiselanyl)ethane Cas:628-39-7 manufacturer 4,5-Difluoro-2-methylaniline manufacturer 2-Diisopropylaminoethanol manufacturer Methyl 3-aminosulfonylthiophene-2-carboxylate manufacturer